Tirzepatide
The dual-agonist that is, on almost every measure, outperforming the monotherapy.
Tirzepatide is the first drug to hit both the GLP-1 and GIP receptors, and the head-to-head data has started reshaping prescribing overnight. The desk tracks the trials, the switch decisions, the compounding picture, and the side-effect profile nobody talks about.
This Week's Feature
Inside the Trial That Made Tirzepatide the New Standard
SURMOUNT-5 compared tirzepatide head-to-head with semaglutide for the first time. The read-through reshaped prescribing overnight. Here is what actually happened in the data.
Read the feature → Tirzepatide The Case Against Switching to Tirzepatide Too Soon
Head-to-head data favors tirzepatide on most endpoints. That does not mean every patient on semaglutide should switch. Three scenarios where the numbers lie.
Tirzepatide Tirzepatide Is Doing Something Semaglutide Cannot
The weight-loss advantage is real. The mechanism explanation is more interesting: the GIP axis matters in ways the field spent a decade dismissing. Here is what changed.